Monday, 16 July 2018 - 5:48
  • it
  • de
  • en
  • fr

Bayer

Recent progress in oncology

The FT has published today, on the occasion of the ASCO congress opening, a complex report about recent medicine progress in the fight against cancer. The area with most research activity and trials is immunotherapy, which generated sales of $3.2bn…

1,000 R&D jobs in Bayer at risk

The economic and financial daily Wirtschaftswoche has published today a brief article reporting that Bayer has initiated an internal project called Super Bowl, to assess all of the company’s research centers. The management’s spokespersons have not disclosed any further details…

Bayer sells part of stake in Covestro for €2.2bn

The Germany-based group Bayer has announced today it has sold another stake in its subsidiary Covestro. The company has sold 14.2% of its stake, namely 28.81 million shares, at €75.5 per share, that is €2.2bn. Bayer is still a stakeholder…

Bayer: Q1 results influenced by negative currency impact

Germany-based pharmaceutical group Bayer has announced its Q1 financial results, which have been below expectations, especially due to the negative currency effect reflecting the dollar’s weakening. Additionally, Bayer’s figures have been affected by a reduction in consumer spending power–especially in…

European competition watchdog approves $66bn Bayer-Monsanto agreement

Bayer has been granted approval to the $66bn acquisition of Monsanto by the European antitrust authorities. The approval is subject to Bayer selling part of its assets–seeds and herbicides–to competitor BASF. Additionally, Bayer has committed to the European Commission to…

Bayer reports serious problems in drug delivery to hospitals and pharmacies

The Bayer group has recently experienced many issues in providing drugs to the market. Bayer’s management just few days ago admitted problems in providing aspirin in solution–named Aspirin i.v.–to physicians and hospitals, since the French contractor was experiencing issues in…

The five causes for Bayer’s disappointing Q4 results

The economic and financial daily Handelsblatt has published a long article analyzing the fourth quarter results announced few days ago by the Bayer group. The author pinpoints 5 causes underlying the disappointing performances reported by the Leverkusen-based company: The acquisition…

Roche’s and Bayer’s strategies compared

If we compare the pipelines and M&A activities of Germany-based Bayer and Switzerland-based Roche, it is clear that the strategies developed by the two groups have much in common.  Bayer signed on November 14th an agreement with Loxo Oncology worth…

BASF strikes its largest acquisition ever

Germany-based BASF some days ago announced its largest acquisition ever: indeed, the Ludwigshafen-based group last Friday reported it had successfully completed the negotiations to acquire a significant part of Bayer’s seed business for €5.9bn–that is 15x EBITDA. The acquired asset…

Bayer sells 10% of stake in Covestro and raises €1.2bn

Bayer sold as much as €19m in shares in its subsidiary Covestro between Wednesday and Thursday, at €63.25 per share, to various investment funds. The transaction fetched the Leverkusen-headquartered group approximately €1.2bn, although the company still owns 31.5% of Covestro….

Bayer appoints new CFO

Germany-based Bayer keeps replacing its top management. Shortly after the new CEO Werner Baumann has taken office, the Leverkusen-based group yesterday afternoon announced the name of its next CFO – Wolfgang Nickl, current CFO at Dutch group ASML, who will…

Xarelto significantly reduces major cardiovascular events

Results from the Phase III COMPASS study found that Xarelto (rivaroxaban) 2.5 mg twice daily, plus aspirin 100 mg once daily, significantly reduced the risk of major cardiovascular events: the rate of CV death, heart attack or stroke decreased by…

Bayer lowers 2017 guidance

Germany-based chemical-pharmaceutical group Bayer today announced it lowered its EBITDA guidance for the current year, due to the ongoing economic crisis in Brazil, which resulted in a sharp decline of pesticide sales. Additionally, poor performance from the Consumer Health division…

FDA puts Bayer’s copanlisib on fast track

Bayer issued today, before trading opened, a press release to announce that US FDA granted priority review – from 10 to 6 months – to assess investigational drug copanlisib, a PI3K inhibitor for the treatment of refractory follicular lymphoma, a…

Werner Baumann’s board loses Bayer’s shareholders’ confidence

Werner Baumann will face Bayer’s shareholders at Friday’s general meeting and it will not be easy for the new CEO to address the criticism over the expensive deal with Monsanto. Specifically, shareholders such as Deka and Union Investment will object…

Bayer ready to sell 3 products to facilitate merger with Monsanto

Bayer is likely to sell a part of its assets generated by selling and commercializing seeds in order to facilitate the approval of its merger with Monsanto by antitrust authorities, Reuters reported yesterday. Instead, no asset of Monsanto’s will reportedly…

Bayer and Monsanto ready to sell assets for $2.5bn

German-based Bayer and US-based Monsanto are reportedly about to sell assets for a minimum of $2.5bn in order to facilitate the approval of their $66bn mega-merger by antitrust authorities. Soybean, cotton and canola seed (oil) assets, as well as brands…

Bayer to sell 10.9% of stake in Covestro and to raise €1.5bn

Bayer announced yesterday evening it plans to sell a part of its 64.2% stake in subsidiary Covestro. The company informed this morning, before stock markets opened, that it has offered to the market 22 million Covestro shares, equaling 10.9% of…

European antitrust authorities’ view on mega mergers ($222bn)

The European antitrust authorities are reportedly assessing three large mergers announced last year in the chemistry business, for a total value of as much as €222bn. These transactions are the $122bn Dow Chemical-DuPont merger, Bayer’s acquisition of Monsanto ($57bn), and…

A picture of Werner Baumann’s Bayer

The German daily Handelsblatt published a long interview to Bayer’s new CEO Werner Baumann (54), providing a 360-degree view on future Bayer. Baumann has been leading the Ludwigshafen-headquartered group for few months—since May 2016—yet he has already completed the largest…

Bayer and Versant invest in stem cells

Bayer AG and Versant Ventures today announced their commitment to invest a minimum of $225m in BlueRock Therapeutics, a Toronto-based company developing and marketing induced pluripotent stem cell (iPSC) therapies, especially used to restore the functions of cells damaged by…

Bracco approaches Bayer about Radiology business (€4bn)

Italian-based Bracco is reportedly targeting Bayer’s Radiology business, valued at approximately €4bn. Also France-based Guerbet is said to be about to place a bid for Bayer. Private equities Advent, Carlyle and Cinven are reported to be targeting the Leverkusen-based group’s…

Bayer exploring sale of Radiology business ($3bn)

Bayer is reportedly exploring the sale of its Radiology business, valued over $3bn by analysts, to a private equity. The choice is not said to originate from the need to raise capital to finance the takeover of Monsanto, but to…

20 banks behind the Bayer-Monsanto mega-deal

At least 20 banks have financed the $56.9bn Bayer-Monsanto mega-deal. Some banks are bookrunners, others support Bayer as lead arrangers, with $4.5bn and $1.125bn holdings respectively. The main financiers include BoA, Merrill Lynch, Credit Suisse, Goldman Sachs, HSBC and J.P….